RXRX — Recursion Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.23bn
- $1.70bn
- $74.68m
Buzz Us Stocks On The Move: Tesla, Warner Bros Discovery, Netflix
U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix
Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial (updated)
Recursion climbs as experimental drug reduces polyp growth in rare disease trial
Brief: Recursion's Tupelo Trial Phase 1B/2 Results Show Polyp Burden Reductions In FAP At 25 Weeks
Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial
Brief: Recursion to Host Webinar on Tupelo Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis on Dec. 8
Recursion Q3 revenue misses estimates, net loss widens
Brief: Recursion Pharmaceuticals Inc - Announces Roche's Exercise Of Option For Microglia Map - SEC Filing
AI-driven drug discovery picks up as FDA pushes to reduce animal testing
Recursion Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Recursion's Q2 revenue beats estimates
U.S. STOCKS ON THE MOVE-Citigroup, Boeing, Calavo Growers
U.S. STOCKS ON THE MOVE-Academy Sports, energy stocks, FirstEnergy
U.S. STOCKS ON THE MOVE-United Natural Foods, Insmed, MacroGenics
Recursion to lay off 20% of workforce amid biotech funding woes (updated)
U.S. STOCKS ON THE MOVE-Novo Nordisk, TechTarget, Unicycive Therapeutics
Recursion Pharma climbs after 20% staff reduction
Brief: Recursion Pharmaceuticals Announces Personnel And Infrastructure Reduction - SEC Filing